September 01, 2009 09:04 ET

Brigham and Women's Hospital Selects ValiMed™ by CDEX as Part of Its Medication Safety Program

TUCSON, AZ--(Marketwire - September 1, 2009) - CDEX Inc. (OTCBB: CEXI) ( announces that Brigham and Women's Hospital (Boston, MA) has selected the CDEX ValiMed™ Medication Safety System as part of its Medication Safety Program. Studies worldwide continue to show that mistakes in the compounding of high-risk medications occur and result in substantial harm to patients and economic loss to hospitals. In an 18-month University of Michigan Health System study, ValiMed identified 5 major medical errors (see ValiMed is used to validate the compounding of high-risk liquid medications in a pharmacy setting and also as a verification program to reduce the diversion of return narcotics in hospitals and other healthcare facilities.

"We selected two ValiMed units to provide additional assurance of accuracy for our robotic compounding and to validate the return of narcotics," said William Churchill, Executive Director of Pharmacy. "Assuring the safety of our patients is job one at Brigham and ValiMed will help with that goal."

"Brigham and Women's Hospital joins the list of other world class hospitals that have selected ValiMed as part of their Medication Safety Program and we look forward to working with Bill and his staff to integrate ValiMed into their daily practices," said Greg Firmbach, CDEX Senior Vice President.

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information